46
MEDYA
TR
EN
Home
Genel
News Detail
Morning Star
May 28, 2026
|
19:00
Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
...
Full Story at Source
Related News
Deadline Approaching: Phreesia Inc. (PHR) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Verallia: Result of the Option to Receive the 2025 Dividend Payment in New Shares
Ansay & Associates Supports Local Communities Through Volunteer Time, Charitable Giving and Development Efforts
Here's the real story behind the record drop in America's oil reserves